Boron neutron capture therapy for glioblastoma multiforme: Clinical studies in Sweden

Journal of Neuro-Oncology

Volumn 62, Issue 1, 2003, Pages 135-144

  Capala, Jacek ^a,b   Stenstam, Britta H ^c   Sköld, Kurt ^a   Rosenschöld, Per Munck ^a,d   Giusti, Valerio ^e   Persson, Charlotta ^a   Wallin, Eva ^c   Brun, Arne ^f   Franzen, Lars ^g   Carlsson, Jörgen ^b   Salford, Leif ^f   Ceberg, Crister ^d   Persson, Bertil ^d   Pellettieri, Luigi ^h   Henriksson, Roger ^g  

^a Studsvik Medical   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Landstinget Sörmland   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e UNIVERSITY OF PISA   (Italy)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BNCT; Boron neutron capture therapy; Boronophenylalanine; Clinical trials; Glioblastoma multiforme; Radiation therapy

Indexed keywords

4 BORONOPHENYLALANINE; BORON;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRANIOTOMY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; IRRADIATION; MALE; MEDICAL SOCIETY; NEUTRON CAPTURE THERAPY; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; SWEDEN; TOXICITY; TREATMENT PLANNING;

EID: 0037847454     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023230801571     Document Type: Article

References (18)

1. Briesmeister JF: MCNP - A General Monte Carlo N-Particle Transport Code. Version 4B, LA-12625-M, Los Alamos National Laboratory, USA, 1997
2. DOORS3.2: One, Two- and Three-Dimensional Discrete Ordinates Neutron/Photon Transport Code System. RSICC CODE PACKAGE CCC-650, 1998
3. Chanana AD, Capala J, Chadha M, Coderre JA, Diaz AZ, Elowitz EH, Iwai J, Joel D, Liu HB, Ma R, Pendzick N, Peress NS, Shady MS, Slatkin DN, Tyson GW, Wielopolski L: Boron neutron capture therapy for glioblastoma multiforme: Interim results from the phase I/II dose-escalation studies. Neurosurgery 44: 1182-1192; discussion 1182-1192, 1999
4. Aziz T, Press NS, Diaz AZ, Capala J, Chanana AD: Postmortem neuropathological features secondary to boron neutron capture therapy for glioblastoma multiforme. J Neuropathol Exp Neurol 50: 62-73, 2000
5. Diaz AZ, Coderre JA, Chanana AD, Ma R: Boron neutron capture therapy for malignant gliomas. Ann Med 32: 81-85, 2000
6. MacDonald D: Response criteria for phase II studies of supratentorial malignant glioma, JCO 8: 1277-1280, 1990
7. Coderre JA, Morris GM: The radiation biology of boron neutron capture therapy. Radiat Res 151: 1-18, 1999
8. Coderre JA, Gavin PR, Capala J, Ma R, Morris GM, Button TM, Tariq A, Peress NS: Tolerance of the normal canine brain to epithermal neutron irradiation in the presence of p-boronophenylalanine. J Neuro-Oncol 48: 27-40, 2000
9. Nigg DW, Wheeler FJ, Wessol DE, Capala J, Chadha M: Computational dosimetry and treatment planning for boron neutron capture therapy. J Neuro-Oncol 33: 93-104, 1997
10. Wheeler FJ, Nigg DW: Three-dimensional radiation dose distribution analysis for boron neutron capture therapy. Nucl Sci Eng 110: 16-31, 1992
11. Elowitz EH, Bergland, RM, Coderre JA, Joel DD, Chadha M, Chanana AD: Biodistribution of p-boronophenylalanine in patients with glioblastoma multiforme for use in boron neutron capture therapy. Neurosurgery 42: 463-469, 1998
12. Coderre, JA, Chanana AD, Joel DD, Elowitz EH, Micca PL, Nawrocky MM, Chadha M, Gebbers, JO, Shady M, Peress NS, Slatkin DN: Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: Boron concentration correlates with tumour cellularity. Radiat Res 149: 163-170, 1998
13. Bauer WF, Micca PL, White BM: A rapid method for the direct analysis of boron in whole blood by atomic emission spectroscopy. In: Soloway AH, Barth RF, Carpenter DE (eds) Advances in Neutron Capture Therapy. Plenum Press, New York, pp 403-407, 1993
14. Smith DR, Chandra S, Barth RF, Yang W, Joel DD, Coderre JA: Quantitative imaging and microlocalization of boron-10 in brain tumors and infiltrating tumor cells by SIMS ion microscopy. Relevance to neutron capture therapy. Cancer Res 61: 8179-8187, 2001
15. Joel DD, Coderre JA, Micca PL, Naawrocky MM: Effects of dose and infusion time on the delivery of p-boronophenyalanine for neutron capture therapy. J Neuro-Oncol 41: 213-221, 1999
16. Wittig A, Sauerwein WA, Coderre JA: Mechanisms of transport of p-boronophenylalanine through the cell membrane in vitro. Radiat Res 153: 173-180, 2000
17. Kankaanranta L, Seppälä T, Kalli M, Karila J, Aschan C, Seren T, Kortesniemi M, Kotiluoto, E, Järviluoma E, Kulvik M, Laakso J, Brander A, Jääskeläinen J, Vähätalo J, Auterinen I, Savolainen S, Färkkilä M, Joensuu H: First clinical results in the Finnish study on BPA-mediated BNCT in glioblastoma. In: Proceedings of the Ninth International Symposium on Neutron Capture Therapy for Cancer. Osaka, Japan, October, 2000
18. Busse PM, Zamenhof RG, Harling OK, Kalpan I, Kaplan J, Chuamg CF, Goorley JT, Kiger III WD, Railey KJ, Tang J, Solares GR, Plamer MR: The Harvard-MIT BNCT program. Overview of the clinical trails and translational research. In: Hawthorne MF, Shelly K, Wiersema RJ (eds) Frontiers in Neutron Capture Therapy. Kluwer Academic/Plenum Publishers, New York, Boston, Dordrecht, London, Moscow, pp 37-60, 2001